Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bupivacaine + levobupivacaine** denotes a putative combination of two long-acting amino-amide local anesthetics. Bupivacaine is the racemic drug substance, whereas levobupivacaine is its single S-enantiomer; consequently, this combination would add levobupivacaine to a preparation already containing the S-enantiomer as part of racemic bupivacaine. Both agents reversibly and use-dependently inhibit voltage-gated sodium channels in peripheral nerves, suppressing action-potential initiation and propagation to produce local or regional anesthesia and analgesia. No specific marketed, registered clinical-development, or standardized co-formulated product containing exactly these two active ingredients was identified.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + levobupivacaine.